DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Launched by HOFFMANN-LA ROCHE · Oct 24, 2002
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women 55-80 years of age;
- • post-menopausal for \>=5 years;
- • ambulatory.
- Exclusion Criteria:
- • malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);
- • breast cancer within the previous 20 years;
- • allergy to bisphosphonates;
- • previous treatment with an intravenous bisphosphonate at any time;
- • previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within the last year, or \>3 months of treatment within the last 2 years.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Little Rock, Arkansas, United States
Omaha, Nebraska, United States
Darlinghurst, , Australia
Pretoria, , South Africa
Barcelona, , Spain
Madrid, , Spain
Madrid, , Spain
Albuquerque, New Mexico, United States
San Antonio, Texas, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Hamburg, , Germany
Montreal, Quebec, Canada
St Louis, Missouri, United States
Omaha, Nebraska, United States
Gainesville, Florida, United States
Berlin, , Germany
Berlin, , Germany
Billings, Montana, United States
Manchester, Greater Manchester, United Kingdom
Little Rock, Arkansas, United States
Madison, Wisconsin, United States
Saskatoon, , Canada
Melbourne, Victoria, Australia
Toronto, Ontario, Canada
Santander, , Spain
Madison, Wisconsin, United States
Melbourne, , Australia
Sydney, , Australia
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Mexico City, , Mexico
Monterrey, , Mexico
New York, New York, United States
Krakow, , Poland
Irvine, California, United States
Rancho Mirage, California, United States
Gainesville, Florida, United States
Bethesda, Maryland, United States
Billings, Montana, United States
Wyomissing, Pennsylvania, United States
Liege, , Belgium
Aalborg, , Denmark
Ballerup, , Denmark
Vejle, , Denmark
Lyon, , France
Budapest, , Hungary
Siena, , Italy
Valeggio Sul Mincio, , Italy
Haugesund, , Norway
Oslo, , Norway
Stavanger, , Norway
Cape Town, , South Africa
Barcelona, , Spain
Leesburg, Florida, United States
Coeur D'alene, Idaho, United States
St Louis, Missouri, United States
Bismarck, North Dakota, United States
Fargo, North Dakota, United States
Rapid City, South Dakota, United States
Virginia Beach, Virginia, United States
Nedlands, , Australia
St. Leonards, , Australia
Bruxelles, , Belgium
Laval, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Plzen, , Czech Republic
Praha, , Czech Republic
København, , Denmark
århus, , Denmark
Orleans, , France
Bochum, , Germany
Hamburg, , Germany
Arenzano, , Italy
Grudziadz, , Poland
Sommerset West, , South Africa
Santander, , Spain
Aberdeen, , United Kingdom
Manchester, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials